3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
NET
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
3
Thyroid Neoplasms
2
Brain Neoplasms
2
Thyroid Cancer, Papillary
1
Thoracic Neoplasms
1
Sarcoma
1
Salivary Gland Neoplasms
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Neoplasms by Site
1
Neoplasms
1
Melanoma
1
Lymphoma, Large-Cell, Anaplastic
1
Lung Neoplasms
1
Intestinal Neoplasms
1
Intestinal Diseases
1
Head and Neck Neoplasms
1
Gastrointestinal Neoplasms
1
Gastrointestinal Diseases
1
Digestive System Neoplasms
1
Digestive System Diseases
1
Colorectal Neoplasms
1
Colonic Diseases
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
Carcinoma, Bronchogenic
1
Bronchial Neoplasms
1
Interventions
Oxaliplatin
3
Irinotecan
3
Surveys and Questionnaires
2
Specimen Handling
2
Radiosurgery
2
Leucovorin
2
Ketamine
2
Hydroxychloroquine
2
Fluorouracil
2
Capecitabine
2
ulixertinib
1
tegafur-gimeracil-oteracil
1
regorafenib
1
pazopanib
1
lanreotide
1
fludarabine phosphate
1
fludarabine
1
dostarlimab
1
dolasetron
1
dexamethasone acetate
1
dexamethasone 21-phosphate
1
danvatirsen
1
cobimetinib
1
brivanib
1
auricularum
1
atezolizumab
1
alectinib
1
aldesleukin
1
abelacimab
1
Tomography, X-Ray Computed
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Gastrointestinal Neoplasms
×
alectinib
×
Clear all
NCT04644315
2023-08-07
ALpha-T
Hoffmann-La Roche
Phase 2
Terminated
1 enrolled
5 charts